RVL Pharmaceuticals PLC reports results for the quarter ended in December - Earnings Summary

RVL Pharmaceuticals

30/03/2022 22:54

* RVL Pharmaceuticals PLC  RVLP.OQ  reported a quarterly
adjusted
loss of 30 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 27 cents per share.
    * Revenue fell 91.7% to $2.86 million from a year ago; 
analysts
expected $3.10 million. 
    * RVL Pharmaceuticals PLC's reported EPS for the quarter was
a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * RVL Pharmaceuticals PLC shares had risen by 62.0% this
quarter.
    * The company reported a quarterly loss of $19.72 million.
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 30 at 09:53 p.m.  ​All
figures in US dollars unless otherwise stated